Pfizer - Latest News [Page 1]

IBRANCE® (palbociclib) to be funded

Wednesday, 15 January 2020, 11:14 am | Pfizer

Pfizer New Zealand today welcomed the provisional decision by PHARMAC to fund IBRANCE (palbociclib) for women with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2–) advanced or metastatic breast cancer ... More >>

Significant New Breast Cancer Treatment Available in NZ

Monday, 4 September 2017, 8:47 am | Pfizer

An entirely new form of anti-cancer therapy that works to apply the brakes to cancer cell division and growth can now be prescribed for New Zealand women with a common and incurable type of breast cancer. More >>

Educational Lung Cancer Poster - Lung Cancer Awareness Month

Monday, 3 November 2014, 11:34 am | Pfizer

Pfizer New Zealand will launch an educational poster about lung cancer, to hang in the foyer of Christchurch Hospital, to help raise awareness of lung cancer and its symptoms as part of Lung Cancer Awareness Month in November. More >>

Pfizer launches a stronger Smokefree Workplace Policy

Tuesday, 29 May 2012, 10:03 am | Pfizer

Pfizer launches a stronger Smokefree Workplace Policy and new quit smoking resources for Kiwis on World Smokefree Day More >>

Innovative new product will help New Zealand lamb

Monday, 30 August 2010, 12:56 pm | Pfizer

Pfizer Animal Health launched an innovative new drench to New Zealand sheep farmers, which could help save our country’s valuable lamb industry millions of dollars a year in lost productivity. More >>

Smokers Offered One of Best-Ever Odds of Quitting

Thursday, 2 August 2007, 3:36 pm | Pfizer

Kiwi smokers throughout New Zealand now have access to a ground-breaking new product called CHAMPIX® (varenicline) which offers them one of their best-ever odds for breaking their addiction to nicotine. More >>

Pfizer Launches New Cancer Treatment In NZ

Friday, 4 May 2007, 10:24 am | Pfizer

The availability in New Zealand of Pfizer’s new cancer treatment Sutent (sunitinib malate), for two hard-to-treat cancers has been welcomed by leading oncologists in both Australia and New Zealand, said Pfizer Australia and New Zealand Senior Medical ... More >>

Pfizer Launches New Cancer Treatment in NZ

Thursday, 3 May 2007, 4:56 pm | Pfizer

The availability in New Zealand of Pfizer’s new cancer treatment Sutent (sunitinib malate), for two hard-to-treat cancers has been welcomed by leading oncologists in both Australia and New Zealand, said Pfizer Australia and New Zealand Senior Medical ... More >>

Survey: Communication Gap Between Doctors, Smokers

Monday, 26 March 2007, 2:55 pm | Pfizer

Most doctors and smokers agree that quitting smoking is the best way to improve health Smokers say they get advice on how to quit smoking half as often as doctors say they provide it More >>

Pharmaceutical Research And Development In NZ

Tuesday, 30 May 2006, 11:52 am | Pfizer

Pharmaceutical companies are abandoning research and development in New Zealand due to a lack of government support, potentially costing the country $100 million in lost investment, according to a report released today. More >>

Daily Mouth Rinse Essential to Good Oral Care

Wednesday, 3 May 2006, 3:16 pm | Pfizer

Auckland, 3 May 2006 –Adding New Zealand’s favorite mouthwash *, Listerine Antiseptic Mouthwash, to your daily routine is now clinically proven to provide significantly greater results over brushing alone. More >>

PHARMAC response to UMR survey misleading

Tuesday, 21 February 2006, 5:09 pm | Pfizer

PHARMAC’s response to the UMR survey released today by Pfizer is statistically misleading, and yet again fails to adequately address concerns raised about its performance and access to medicines, Mark Crotty said. More >>

Pfizer Disappointed By Weak Pharmac Response

Wednesday, 31 August 2005, 7:12 pm | Pfizer

Pfizer New Zealand is disappointed, but not surprised, that PHARMAC has failed to address any of the serious issues that have been raised in the Alex Sundakov report on the impact of the country's restrictive medicines policy on the health and well ... More >>

Public strongly supports review of Pharmac

Monday, 29 August 2005, 6:17 pm | Pfizer

Almost seven-in-ten adult New Zealanders strongly support an independent review of the Government’s medicines funding agency Pharmac, according to a survey conducted by UMR Insight last month. More >>

Pharmac Finally Funds World Class Pain Medication

Friday, 24 June 2005, 8:55 am | Pfizer

PFIZER New Zealand has welcomed PHARMAC's decision to widen access to its leading neuropathic pain medication by funding the medicine from 1 July this year, Pfizer General Manager Mark Crotty said today. More >>

Pfizer NZ Response To Medsafe Announcement

Friday, 29 April 2005, 11:28 am | Pfizer

Pfizer New Zealand Ltd welcomes the announcement by Medsafe that it has revised its earlier advice, and will keep the company’s COX-2 inhibitor arthritis medication, Celebrex, on the market, Pfizer New Zealand General Manager Mark Crotty said. More >>

Pfizer New Zealand Response To The IMMP Assertions

Friday, 15 April 2005, 9:28 am | Pfizer

Pfizer New Zealand today strongly disagrees with the statement issued by the IMMP, Pfizer General Manager Mark Crotty said. More >>

Pfizer New Zealand Bextra Advisory

Tuesday, 12 April 2005, 9:35 am | Pfizer

11 April 2005 PFIZER NEW ZEALAND BEXTRA ADVISORY Pfizer New Zealand will voluntarily suspend the marketing and distribution of Bextra and withdraw the product to pharmacy level, following a request from the regulator Medsafe. Pfizer New Zealand general ... More >>

Pfizer voluntarily withdraws Bextra from NZ

Tuesday, 12 April 2005, 9:31 am | Pfizer

Pharmaceutical company Pfizer is voluntarily withdrawing the Cox-2 medicine Bextra from the New Zealand market following a request from Medsafe to suspend distribution and marketing, and will recall supplies of Bextra progressively from wholesale and ... More >>

Pfizer New Zealand Waiting For Medsafe Advice

Friday, 8 April 2005, 5:02 pm | Pfizer

“Medsafe is currently conducting a review of the safety of the class of Cox-2 inhibitors, including Bextra, the results of which are expected next week,” Pfizer NZ General Manger Mark Crotty said today. More >>

 

 

InfoPages Links

 
 
 
 
 

LATEST HEADLINES

  • PARLIAMENT
  • POLITICS
  • REGIONAL